RxSight, Inc.
No enriched coverage for $RXST in the last 7 days.
No SEC Form 4 filings for $RXST in the last 30 days.
RxSight, Inc. (RXST) reported stronger-than-expected Q1 earnings, beating analyst estimates by $0.12 with an EPS of ($0.19). The company also surpassed revenue expectations, bringing in $30.9 million against a consensus estimate of $29.75 million. The stock is currently trading at $6.78, reflecting a 6.61% drop today.
RxSight (NASDAQ: RXST) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, with management hosting a fireside chat at 8:00 a.m. PT. While this event signals ongoing investor engagement, historical data suggests that conference participation announcements typically result in modest stock movements compared to financial updates or leadership changes. Investors are advised to focus on the company's execution against 2026 guidance and future operational milestones rather than this presentation for significant market impact.
William Blair initiated coverage of RxSight, Inc. (RXST) with a "Market Perform" rating due to stalled sales growth expected in 2025 following strong early adoption. The firm awaits evidence of sustained commercial reacceleration, despite the stock's discounted trading. RxSight narrowed its full-year revenue guidance and is focusing on international expansion, but the article suggests greater upside potential in certain AI stocks.
